Sales of Amgen's Blincyto have grown slowly since it was first introduced a decade ago, but have started to gather momentum thanks to expanded use in acute lymphoblastic leukaemia (ALL), which ...

Blincyto is a key contributor to Amgen’s top line and generated sales of $861 million in 2023, rising 48% year over year. Amgen’s other BiTE therapy, which was recently approved in May, was ...

Cullinan Therapeutics (NASDAQ:CGEM) drew Wall Street's attention last week as William Blair touted the stock after peer-reviewed data for Amgen's (NASDAQ:AMGN) leukemia therapy, Blincyto ...

Amgen’s Blincyto has been granted a full European licence in a form of blood cancer following data showing the drug almost doubled overall survival time compared with standard therapy.